Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer

NCT00860158 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Slow accrual; closed by funder

Conditions

Prostate Cancer

Interventions

DRUG: Dasatinib
DRUG: Leuprolide Acetate (LHRH Analogue)
PROCEDURE: Radical Prostatectomy

Sponsor

Noah Hahn, M.D.

Collaborators

[object Object]